neurology
Medicines

News in brief: Infection risk factors with MS treatment; AAN meeting this weekend; Cervical dystonia treatments get Cochrane update

Monitor immunoglobulin levels prior to ocrelizumab initiation A Victorian study that aimed to identify risk factors for infection in patients with MS treated with ocrelizumab has found that higher serum IgA and IgG and older age were associated with reduced odds of infection. The retrospective, observational cohort study involving 185 patients receiving ocrelizumab at the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic